miR-26a-5p restoration via EZH2 silencing blocks the IL-6/STAT3 axis to repress the growth of prostate cancer

References

• Wang L, Lu B, He M, et al. Prostate cancer incidence and mortality: global status and temporal trends in 89 countries from 2000 to 2019. Front Public Health. 2022;10:811044. doi: 10.3389/fpubh.2022.811044
   PubMed Web of Science ®Google Scholar
• Gonzalez-Billalabeitia E, Seitzer N, Song SJ, et al. Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. Cancer Discov. 2014 Aug;4(8):896–904. doi: 10.1158/2159-8290.CD-13-0230
   PubMed Web of Science ®Google Scholar
• Daniunaite K, Dubikaityte M, Gibas P, et al. Clinical significance of miRNA host gene promoter methylation in prostate cancer. Hum Mol Genet. 2017 Jul 1;26(13):2451–2461. doi: 10.1093/hmg/ddx138
   PubMed Web of Science ®Google Scholar
• Karanikolas BD, Figueiredo ML, Wu L. Comprehensive evaluation of the role of EZH2 in the growth, invasion, and aggression of a panel of prostate cancer cell lines. Prostate. 2010 May 1;70(6):675–88. doi: 10.1002/pros.21112
   PubMed Web of Science ®Google Scholar
• Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. J Hematol Oncol. 2020 Jul 28;13(1):104. doi: 10.1186/s13045-020-00937-8
   PubMed Web of Science ®Google Scholar
• Varambally S, Dhanasekaran SM, Zhou M, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature. 2002 Oct 10;419(6907):624–629. doi: 10.1038/nature01075
   PubMed Web of Science ®Google Scholar
• Bachmann IM, Halvorsen OJ, Collett K, et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol. 2006 Jan 10;24(2):268–273. doi: 10.1200/JCO.2005.01.5180
   PubMed Web of Science ®Google Scholar
• Qiu BQ, Lin XH, Ye XD, et al. Long non-coding RNA PSMA3-AS1 promotes malignant phenotypes of esophageal cancer by modulating the miR-101/EZH2 axis as a ceRNA. Aging. 2020 Jan 31;12(2):1843–1856. doi: 10.18632/aging.102716
   PubMedGoogle Scholar
• Gan L, Xu M, Hua R, et al. The polycomb group protein EZH2 induces epithelial-mesenchymal transition and pluripotent phenotype of gastric cancer cells by binding to PTEN promoter. J Hematol Oncol. 2018 Jan 15;11(1):9. doi: 10.1186/s13045-017-0547-3
   PubMedGoogle Scholar
• Pellecchia S, Sepe R, Decaussin-Petrucci M, et al. The Long non-Coding RNA Prader Willi/Angelman region RNA5 (PAR5) is downregulated in anaplastic thyroid carcinomas where it acts as a tumor suppressor by reducing EZH2 activity. Cancers (Basel). 2020 Jan 17;12(1):235. doi: 10.3390/cancers12010235
   PubMed Web of Science ®Google Scholar
• Fan DC, Zhao YR, Qi H, et al. MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma. Auris Nasus Larynx. 2020 Aug;47(4):632–642. doi: 10.1016/j.anl.2019.12.007
   PubMed Web of Science ®Google Scholar
• Krill L, Deng W, Eskander R, et al. Overexpression of enhance of zeste homolog 2 (EZH2) in endometrial carcinoma: an NRG Oncology/Gynecologic Oncology group study. Gynecol Oncol. 2020 Feb;156(2):423–429. doi: 10.1016/j.ygyno.2019.12.003
   PubMed Web of Science ®Google Scholar
• Sun C, Zhao C, Li S, et al. EZH2 expression is increased in BAP1-mutant renal clear cell carcinoma and is related to poor prognosis. J Cancer. 2018;9(20):3787–3796. doi: 10.7150/jca.26275
   PubMed Web of Science ®Google Scholar
• Sashida G, Iwama A. Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies. Int J Hematol. 2017 Jan;105(1):23–30. doi: 10.1007/s12185-016-2124-x
   PubMed Web of Science ®Google Scholar
• Bodor C, O’Riain C, Wrench D, et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia. 2011 Apr;25(4):726–729. doi: 10.1038/leu.2010.311
   PubMed Web of Science ®Google Scholar
• Yap DB, Chu J, Berg T, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011 Feb 24;117(8):2451–2459. doi: 10.1182/blood-2010-11-321208
   PubMed Web of Science ®Google Scholar
• Zhang Q, Han Q, Zi J, et al. Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms. Genes Dis. 2019 Sep;6(3):276–281. doi: 10.1016/j.gendis.2019.05.001
   PubMed Web of Science ®Google Scholar
• Chen YH, Yeh FL, Yeh SP, et al. Myocyte enhancer factor-2 interacting transcriptional repressor (MITR) is a switch that promotes osteogenesis and inhibits adipogenesis of mesenchymal stem cells by inactivating peroxisome proliferator-activated receptor gamma-2. J Biol Chem. 2011 Mar 25;286(12):10671–80. doi: 10.1074/jbc.M110.199612
   PubMed Web of Science ®Google Scholar
• Chang CJ, Hung MC. The role of EZH2 in tumour progression. Br J Cancer. 2012 Jan 17;106(2):243–247. doi: 10.1038/bjc.2011.551
   PubMed Web of Science ®Google Scholar
• Aveta A, Cilio S, Contieri R, et al. Urinary MicroRNAs as biomarkers of urological cancers: a systematic review. Int J Mol Sci. 2023 Jun 29;24(13):10846. doi: 10.3390/ijms241310846
   PubMed Web of Science ®Google Scholar
• Ghorbanmehr N, Gharbi S, Korsching E, et al. miR-21-5p, miR-141-3p, and miR-205-5p levels in urine-promising biomarkers for the identification of prostate and bladder cancer. Prostate. 2019 Jan;79(1):88–95. doi: 10.1002/pros.23714
   PubMed Web of Science ®Google Scholar
• Markert L, Holdmann J, Klinger C, et al. Small RNAs as biomarkers to differentiate benign and malign prostate diseases: an alternative for transrectal punch biopsy of the prostate? PLoS One. 2021;16(3):e0247930. doi: 10.1371/journal.pone.0247930
   PubMed Web of Science ®Google Scholar
• Kang HW, Byun YJ, Moon SM, et al. Urinary hsv2-miR-H9 to hsa-miR-3659 ratio is an effective marker for discriminating prostate cancer from benign prostate hyperplasia in patients within the prostate-specific antigen grey zone. Investig Clin Urol. 2022 Mar;63(2):238–244. doi: 10.4111/icu.20210493
   PubMed Web of Science ®Google Scholar
• Byun YJ, Piao XM, Jeong P, et al. Urinary microRNA-1913 to microRNA-3659 expression ratio as a non-invasive diagnostic biomarker for prostate cancer. Investig Clin Urol. 2021 May;62(3):340–348. doi: 10.4111/icu.20200488
   PubMed Web of Science ®Google Scholar
• Hasanoglu S, Goncu B, Yucesan E, et al. Investigating differential miRNA expression profiling using serum and urine specimens for detecting potential biomarkers for early prostate cancer diagnosis. Turk J Med Sci. 2021 Aug 30;51(4):1764–1774. doi: 10.3906/sag-2010-183
   PubMed Web of Science ®Google Scholar
• Leite KR, Tomiyama A, Reis ST, et al. MicroRNA expression profiles in the progression of prostate cancer–from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol. 2013 Aug;31(6):796–801. doi: 10.1016/j.urolonc.2011.07.002
   PubMed Web of Science ®Google Scholar
• Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007 Jul 1;67(13):6130–6135. doi: 10.1158/0008-5472.CAN-07-0533
   PubMed Web of Science ®Google Scholar
• Ling Z, Wang X, Tao T, et al. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer. J Exp Clin Cancer Res. 2017 Nov 15;36(1):159. doi: 10.1186/s13046-017-0629-7
   PubMedGoogle Scholar
• Samaan S, Lichner Z, Ding Q, et al. Kallikreins are involved in an miRNA network that contributes to prostate cancer progression. Biol Chem. 2014 Sep;395(9):991–1001. doi: 10.1515/hsz-2013-0288
   PubMed Web of Science ®Google Scholar
• Guo K, Zheng S, Xu Y, et al. Loss of miR-26a-5p promotes proliferation, migration, and invasion in prostate cancer through negatively regulating SERBP1. Tumour Biol. 2016 Sep;37(9):12843–12854. doi: 10.1007/s13277-016-5158-z
   PubMedGoogle Scholar
• Lu YY, Lin Y, Ding DX, et al. MiR-26a functions as a tumor suppressor in ambient particulate matter-bound metal-triggered lung cancer cell metastasis by targeting LIN28B-IL6-STAT3 axis. Arch Toxicol. 2018 Mar;92(3):1023–1035. doi: 10.1007/s00204-017-2141-4
   PubMed Web of Science ®Google Scholar
• Sanchis P, Fernandez-Gayol O, Vizueta J, et al. Microglial cell-derived interleukin-6 influences behavior and inflammatory response in the brain following traumatic brain injury. Glia. 2020 May;68(5):999–1016. doi: 10.1002/glia.23758
   PubMed Web of Science ®Google Scholar
• Guo Y, Xu F, Lu T, et al. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 2012 Nov;38(7):904–910. doi: 10.1016/j.ctrv.2012.04.007
   PubMed Web of Science ®Google Scholar
• Azevedo A, Cunha V, Teixeira AL, et al. IL-6/IL-6R as a potential key signaling pathway in prostate cancer development. World J Clin Oncol. 2011 Dec 10;2(12):384–96. doi: 10.5306/wjco.v2.i12.384
   PubMedGoogle Scholar
• Liu Y, Li PK, Li C, et al. Inhibition of STAT3 signaling blocks the anti-apoptotic activity of IL-6 in human liver cancer cells. J Biol Chem. 2010 Aug 27;285(35):27429–27439. doi: 10.1074/jbc.M110.142752
   PubMed Web of Science ®Google Scholar
• Liu C, Zhu Y, Lou W, et al. Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells. Prostate. 2014 Feb;74(2):201–209. doi: 10.1002/pros.22741
   PubMed Web of Science ®Google Scholar
• Paner GP, Stadler WM, Hansel DE, et al. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018 Apr;73(4):560–569. doi: 10.1016/j.eururo.2017.12.018
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin. 2022 Jan;72(1):7–33. doi: 10.3322/caac.21708
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Park SH, Fong KW, Mong E, et al. Going beyond polycomb: EZH2 functions in prostate cancer. Oncogene. 2021 Sep;40(39):5788–5798. doi: 10.1038/s41388-021-01982-4
   PubMed Web of Science ®Google Scholar
• Park SH, Fong KW, Kim J, et al. Posttranslational regulation of FOXA1 by Polycomb and BUB3/USP7 deubiquitin complex in prostate cancer. Sci Adv. 2021 Apr;7(15). doi: 10.1126/sciadv.abe2261
   Web of Science ®Google Scholar
• Xu K, Wu ZJ, Groner AC, et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent. Science. 2012 Dec 14;338(6113):1465–1469. doi: 10.1126/science.1227604
   PubMed Web of Science ®Google Scholar
• Kim J, Lee Y, Lu X, et al. Polycomb- and methylation-independent roles of EZH2 as a transcription activator. Cell Rep. 2018 Dec 4;25(10):2808–2820 e4. doi: 10.1016/j.celrep.2018.11.035
   PubMed Web of Science ®Google Scholar
• Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014 Jun;113(6):986–992. doi: 10.1111/bju.12452
   PubMed Web of Science ®Google Scholar
• Wang C, Ding T, Yang D, et al. The lncRNA OGFRP1/miR-149-5p/IL-6 axis regulates prostate cancer chemoresistance. Pathol Res Pract. 2021 Aug;224:153535.
   PubMed Web of Science ®Google Scholar
• Gandellini P, Folini M, Longoni N, et al. miR-205 exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase cepsilon. Cancer Res. 2009 Mar 15;69(6):2287–95. doi: 10.1158/0008-5472.CAN-08-2894
   PubMed Web of Science ®Google Scholar
• Sung SY, Liao CH, Wu HP, et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One. 2013;8(8):e71637. doi: 10.1371/journal.pone.0071637
   PubMed Web of Science ®Google Scholar
• Steiner H, Cavarretta IT, Moser PL, et al. Regulation of growth of prostate cancer cells selected in the presence of interleukin-6 by the anti-interleukin-6 antibody CNTO 328. Prostate. 2006 Dec 1;66(16):1744–1752. doi: 10.1002/pros.20492
   PubMed Web of Science ®Google Scholar
• Gaykalova DA, Manola JB, Ozawa H, et al. NF-kappaB and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma. Int J Cancer. 2015 Oct 15;137(8):1879–89. doi: 10.1002/ijc.29558
   PubMed Web of Science ®Google Scholar
• Lee DS, O’Keefe RA, Ha PK, et al. Biochemical properties of a decoy oligodeoxynucleotide inhibitor of STAT3 transcription factor. Int J Mol Sci. 2018 May 30;19(6):1608. doi: 10.3390/ijms19061608
   PubMed Web of Science ®Google Scholar
• Schroeder A, Herrmann A, Cherryholmes G, et al. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014 Feb 15;74(4):1227–1237. doi: 10.1158/0008-5472.CAN-13-0594
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fujita K, Nojima S, et al. High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling. Clin Cancer Res. 2018 Sep 1;24(17):4309–4318. doi: 10.1158/1078-0432.CCR-18-0106
   PubMed Web of Science ®Google Scholar
• Di Minno A, Aveta A, Gelzo M, et al. 8-hydroxy-2-deoxyguanosine and 8-iso-prostaglandin F2α: putative biomarkers to assess oxidative stress damage following robot-assisted radical prostatectomy (RARP). J Clin Med. 2022 Oct 17;11(20):6102. doi: 10.3390/jcm11206102
   PubMed Web of Science ®Google Scholar